Target Advancement: Tool Generation and Target Validation
Event details
| Date | 28.09.2021 |
| Category | Call for proposal |
| Event Language | English |
Aim: The Target Advancement Program seeks to build conclusive evidence around and develop field-enabling tools for early-stage biological targets in Parkinson’s Disease (PD) in order to enable the initiation of future preclinical therapeutic programs focused on those targets. Funding will support projects to
validate early-stage targets previously implicated in PD pathophysiology and/or symptomology but that have not yet been rigorously investigated for their ability to impact disease-relevant outcomes in PD model systems. For targets that are lacking preclinical tools and/or models required for validation, the Tool Generation track provides funding for the development of research-enabling preclinical tools and models to assist with the validation of the selected target.
For this round, MJFF will not consider proposals focused on the following:
Duration: 18 to 24 months
Deadline:
validate early-stage targets previously implicated in PD pathophysiology and/or symptomology but that have not yet been rigorously investigated for their ability to impact disease-relevant outcomes in PD model systems. For targets that are lacking preclinical tools and/or models required for validation, the Tool Generation track provides funding for the development of research-enabling preclinical tools and models to assist with the validation of the selected target.
For this round, MJFF will not consider proposals focused on the following:
- Validation of well-known targets, including alpha-synuclein, LRRK2, GBA and Parkin/PINK1 given significant current investments MJFF is already making in these areas.
- Applications proposing discovery studies to identify new targets (e.g., large-scale screening or genomic/transcriptomic analyses).
Duration: 18 to 24 months
Deadline:
- Pre-proposals Due: 28 September 2021, 5 p.m. US ET
- Full Proposals Due (by invite only): January 13, 2022, 5 p.m. US ET
- U.S. and non-U.S. biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities; and
- U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.
- Post-doctoral fellows are eligible to apply as co-investigators with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research. The administrative co-PI will be responsible for assisting in providing all institutional documents required for the project and will be required to sign any award contract. Training or mentoring-only proposals will not be considered.
- Download the RFA overview and application template.
- Log in or create an account in the grant application portal.
- Submit your completed application.
- Email [email protected] for specific questions
- Contact the Research Office at [email protected] if you have general questions or if you decide to submit a proposal.
Practical information
- General public
- Free
Organizer
- The Research Office